In the possible event of a pandemic, the UK has secured 5 million doses of an H5 influenza vaccine to stay one step ahead of the avian influenza virus.
One in eight adults (12.7%) who are infected with SARS-CoV-2 experience long COVID symptoms, including chest pain, difficulties breathing, painful muscles and more.
Worldwide and national crises and political unrest can threaten any organisation, no matter how healthy it is, here's how to deal with it in your company.
Smokers or vapers prior to hospitalisation for COVID-19 were more likely to experience severe complications, and die from COVID-19, than their counterparts.
Using almost $30 million in funding, an all-in-one vaccine is being developed to bring new protection against a range of new and existing coronavirus variants.
In a huge blow to Boris Johnson’s government, ministers, parliamentary private secretaries, and more have begun a mass cabinet resignation. What’s next?
The most recent omicron subvariants have caused new infection spikes across the United States, as researchers find they are better at eluding vaccines.
![Figure 1. Systemic immune responses elicited by oral dmLT-saponin combinations compared to injected vaccines (A) Cryo-electron microscopy (cryo-EM) image of the dmLT and saponin formulation demonstrating the formation of acid-stable micelle particles upon the addition of saponin to dmLT. (B) Preclinical evaluation of systemic serum IgG and IgA antibody responses following prime/boost vaccination. Antibody levels against the microbial protein antigen included in the vaccination were assessed two weeks post-final vaccination in immunized mice. Groups were stratified by vaccination route (intramuscular [IM] or sublingual [SL]) and adjuvant formulation (dmLT [D] and/or saponin [S]). Comparisons with unvaccinated controls (white bars) are shown. Statistical significance between groups is indicated (*P < 0.05), with the SL D+S group achieving the best IgG and IgA responses to vaccine antigen.](https://www.openaccessgovernment.org/wp-content/uploads/2025/01/Figure-01.jpg)
